Novo Nordisk Bolsters Metabolic Pipeline With Hengrui Licensing Deal as Buyback Tranche Tops 11.2 Billion DKK

Novo Nordisk licensed Hengrui's oral GLP-1/GIP candidate for up to USD 2.6 billion and reported real-world data on semaglutide's cardiovascular edge.

Novo Nordisk is pressing ahead with a dual strategy of external dealmaking and internal data generation as it seeks to defend its position in the increasingly crowded metabolic disease arena. The Danish drugmaker confirmed a fresh licensing arrangement and released practice-based evidence for its flagship therapy, while also updating investors on its capital return program.

Oral GLP-1/GIP Candidate Joins the Fold

At the heart of the pipeline announcement is an agreement with Hengrui Pharma that hands Novo Nordisk exclusive rights to develop, manufacture and commercialize HRS-1596 outside mainland China, Hong Kong, Macau and Taiwan. The investigational asset is a once-weekly oral dual GLP-1/GIP receptor agonist that is being readied for Phase 1 clinical development.

The deal carries a potential total value of up to USD 2.6 billion, comprising a USD 300 million upfront payment alongside success-based milestone payments tied to development, regulatory and commercial progress. For the group, the in-licensing marks another step toward broadening its footprint beyond injectable formats into tablet-based therapies.

Real-World Data Backs Semaglutide's Cardiovascular Edge

Alongside the licensing news, Novo Nordisk presented a retrospective analysis at the EASD annual meeting covering 636,525 adults with type-2 diabetes. The study compared dose escalation to Ozempic 2 mg against a switch to tirzepatide.

According to the findings, treatment with 2 mg semaglutide was associated with a statistically significant 6 percent lower risk of major cardiovascular events than the therapeutic switch. The data presentation underscores the company's effort to shore up the cardiac benefits of its established therapy amid mounting competition.

The results arrive at a sensitive moment. Rivalry for market share in diabetes and obesity treatments has been intensifying for months, and investors are watching closely to see whether Novo Nordisk can hold its lead. The new outcomes research adds to a string of scientific wins—on 21 September, the company had already published initial results from the Phase 3 REIMAGINE 5 trial, in which the CagriSema combination at a 1.0 mg / 1.0 mg dose achieved an estimated average weight loss of 12.4 percent, versus 9.1 percent for participants on 5 mg tirzepatide.

External Bets Broaden the Technology Base

To widen its technological reach, management has also looked outside the company. On Friday, Novo Nordisk secured rights to the PharmaShell platform technology from Sweden's Nanexa for up to five development programs spanning obesity, type-2 diabetes and cardiometabolic diseases.

Buyback Details and the Next Reporting Date

Rounding out the operational updates, Novo Nordisk confirmed details of its ongoing capital measures on Monday. The overall share buyback program carries a volume of up to DKK 15 billion over a twelve-month period starting 4 February 2026. Within the tranche announced on 6 May, B-shares worth up to DKK 11,200,000,010.45 may be acquired through 1 February 2027.

Attention now turns to the release of nine-month 2026 results, which the company has scheduled for 4 November 2026. The stock has shed 23 percent since the start of the year, closing at EUR 33.77 on the prior trading day before edging up to EUR 33.94 in pre-market action. The upcoming quarterly figures should reveal the extent to which the recent moves to secure long-term market positioning are paying off.

Analysts Stay Cautious After Share Price Declines

Market reaction to the operational repositioning has so far been muted. Despite the latest study data and acquisitions, institutional observers remain guarded. Deutsche Bank cut its price target for the stock from DKK 265 to DKK 245 on 22 September and kept its sell recommendation. On Friday, Bank of America Securities also rated the shares "Hold." For investors, the key question is whether the reported data advantages will be enough to sustainably ease pressure in the cardiometabolic market.